74
Views
5
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already?

&
Pages 513-515 | Published online: 10 Jan 2014

References

  • Safar Zadeh E, Lungu AO, Cochran EK et al. The liver diseases of lipodystrophy: The long-term effect of leptin treatment. J. Hepatol. 59, 131–137 (2013).
  • Javor ED, Ghany MG, Cochran EK et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41, 753–760 (2005).
  • Moon HS, Dalamaga M, Kim SY et al. Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr. Rev. 34(3), 377–412 (2013).
  • Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J. Hepatol. 45, 600–606 (2006).
  • Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat. Rev. Endocrinol. 7, 137–150 (2011).
  • Cartwright BR, Goodman JM. Seipin: from human disease to molecular mechanism. J. Lipid. Res. 53, 1042–1055 (2012).
  • Oral EA, Simha V, Ruiz E, Andewelt A et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 570–578 (2002).
  • Chan JL, Lutz K, Cochran E et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr. Pract. 17, 922–932 (2011).
  • Takahashi Y, Soejima Y, Fukusato T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 18, 2300–2308 (2012).
  • Savage DB. Mouse models of inherited lipodystrophy. Dis. Model. Mech. 2, 554–562 (2009).
  • Simha V, Subramanyam L, Szczepaniak L et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J. Clin. Endocrinol. Metab. 97, 785–792 (2012).
  • Aleffi S, Petrai I, Bertolani C et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42, 1339–1348 (2005).
  • Cao Q, Mak KM, Lieber CS. Leptin represses matrix metalloproteinase-1 gene expression in LX2 human hepatic stellate cells. J. Hepatol. 46, 124–133 (2007).
  • Choi SS, Syn WK, Karaca GF et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J. Biol. Chem. 285, 36551–36560 (2010).
  • Ikejima K, Okumura K, Kon K, Takei Y, Sato N. Role of adipocytokines in hepatic fibrogenesis. J. Gastroenterol. Hepatol. 22(Suppl. 1), S87–S92 (2007).
  • Heymsfield SB, Greenberg AS, Fujioka K et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 282, 1568–1575 (1999).
  • Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J. Clin. Endocrinol. Metab. 85, 4003–4009 (2000).
  • Mittendorfer B, Horowitz JF, DePaoli AM, McCamish MA, Patterson BW, Klein S. Recombinant human leptin treatment does not improve insulin action in obese subjects with Type 2 diabetes. Diabetes 60, 1474–1477 (2011).
  • Roth JD, Roland BL, Cole RL et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl Acad. Sci. USA 105, 7257–7262 (2008).
  • Ravussin E, Smith SR, Mitchell JA et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17, 1736–1743 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.